BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20016530)

  • 41. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience.
    Navarrete M; Rossi E; Brivio E; Carrillo JM; Bonilla M; Vasquez R; Peña A; Fu L; Martinez R; Espinoza CM; Lacayo LF; Rodriguez H; Batista R; Barr R; Howard SC; Ribeiro RC; Masera G; Biondi A; Conter V; Valsecchi MG
    Pediatr Blood Cancer; 2014 May; 61(5):803-9. PubMed ID: 24376115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Acute lymphoblastic leukemia in childhood: the COALL studies].
    Janka GE; Winkler K; Jürgens H; Göbel U; Gutjahr P; Spaar HJ
    Klin Padiatr; 1986; 198(3):171-7. PubMed ID: 3523023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.
    Mitchell C; Richards S; Harrison CJ; Eden T
    Leukemia; 2010 Feb; 24(2):406-18. PubMed ID: 20010621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
    Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
    Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
    Fronkova E; Mejstrikova E; Avigad S; Chik KW; Castillo L; Manor S; Reznickova L; Valova T; Zdrahalova K; Hrusak O; Jabali Y; Schrappe M; Conter V; Izraeli S; Li CK; Stark B; Stary J; Trka J
    Leukemia; 2008 May; 22(5):989-97. PubMed ID: 18305563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.
    Krishnan S; Wade R; Moorman AV; Mitchell C; Kinsey SE; Eden TO; Parker C; Vora A; Richards S; Saha V
    Leukemia; 2010 Feb; 24(2):450-9. PubMed ID: 20016529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
    Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
    Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
    Escherich G; Tröger A; Göbel U; Graubner U; Pekrun A; Jorch N; Kaspers G; Zimmermann M; zur Stadt U; Kazemier K; Pieters R; Den Boer ML; Horstmann M; Janka GE;
    Haematologica; 2011 Jun; 96(6):854-62. PubMed ID: 21330320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
    Toft N; Birgens H; Abrahamsson J; Bernell P; Griškevičius L; Hallböök H; Heyman M; Holm MS; Hulegårdh E; Klausen TW; Marquart HV; Jónsson OG; Nielsen OJ; Quist-Paulsen P; Taskinen M; Vaitkeviciene G; Vettenranta K; Åsberg A; Schmiegelow K
    Eur J Haematol; 2013 May; 90(5):404-12. PubMed ID: 23461707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
    Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
    Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood--follow up after 9 years. Coall Study Group.
    Janka-Schaub GE; Harms D; Goebel U; Graubner U; Gutjahr P; Haas RJ; Juergens H; Spaar HJ; Winkler K
    Eur J Pediatr; 1996 Aug; 155(8):640-8. PubMed ID: 8839716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
    Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
    Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.
    Alloin AL; Barlogis V; Auquier P; Contet A; Poiree M; Demeocq F; Herrmann I; Villes V; Bertrand Y; Plantaz D; Kanold J; Chastagner P; Chambost H; Sirvent N; Michel G
    Br J Haematol; 2014 Jan; 164(1):94-100. PubMed ID: 24116693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.
    Niehues T; Kapaun P; Harms DO; Burdach S; Kramm C; Körholz D; Janka-Schaub G; Göbel U
    Leukemia; 1999 Apr; 13(4):614-7. PubMed ID: 10214870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current management and challenges of malignant disease in the CNS in paediatric leukaemia.
    Pui CH; Howard SC
    Lancet Oncol; 2008 Mar; 9(3):257-68. PubMed ID: 18308251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Osteonecrosis in paediatric patients with acute lymphoblastic leukaemia treated on Co-ALL-07-03 trial: a single centre analysis.
    Kuhlen M; Moldovan A; Krull K; Meisel R; Borkhardt A
    Klin Padiatr; 2014 May; 226(3):154-60. PubMed ID: 24710762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A practical strategy of monitoring minimal residue disease and intervention for central nervous system relapse of childhood acute lymphoblastic leukemia: a single Chinese center's experience.
    Liang Y; Ca Q; Zhai ZM; Wang NL
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):388-93. PubMed ID: 23787730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
    Enshaei A; O'Connor D; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; den Boer ML; Boer JM; de Groot-Kruseman HA; Marquart HV; Noren-Nystrom U; Schmiegelow K; Schwab C; Horstmann MA; Escherich G; Heyman M; Pieters R; Vora A; Moppett J; Moorman AV
    Blood; 2020 Apr; 135(17):1438-1446. PubMed ID: 32315382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Childhood and adolescent lymphoid and myeloid leukemia.
    Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
    Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
    Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.